Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.31 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.31 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.31 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.31 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.31 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.31 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL665365 | 1.00 | TSHR (0.44) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL692137 | 0.97 | — | — | |
| SCHEMBL255887 | 0.97 | — | — | |
| SCHEMBL3706927 | 0.97 | — | — | |
| Methylene Chloride SCHEMBL28375080 | 0.93 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| Hydrochloric Acid SCHEMBL20305534 | 0.93 | TSHR (0.42) | TSHRGABRR1GABRR2BLMGABRR3 | |
| Hydrochloric Acid SCHEMBL2132221 | 0.84 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| Hydrochloric Acid SCHEMBL2130832 | 0.84 | TSHR (0.39) | TSHRGABRR1GABRR2BLMGABRR3 | |
| SCHEMBL2607971 | 0.84 | — | — | |
| Maleic Acid SCHEMBL22367552 | 0.82 | TSHR (0.38) | TSHRGABRR1GABRR2BLMGABRR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-04 | — | — | US | claimed |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| US-12630552-B2 | Inhibitors of KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2026-05-19 | — | — | US | disclosed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-4695268-A1 | ANTIBACTERIAL COVALENT PEPTIDE INHIBITORS | Université de Bordeaux (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| US-12534742-B2 | Compound for regulating gene editing efficiency and application thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-01-27 | — | — | US | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
| US-20040162442-A1 | Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines | WYETH (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004066919-A2 | SYNTHESIS OF 4AMINO-2-BUTENOYL CHLORIDES AND THEIR USE IN THE PREPARATION OF 3-CYANO QUINOLINES | WYETH (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1414438-A1 | ANTINEOPLASTIC COMBINATIONS | Wyeth (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6617333-B2 | Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methyl propionic acid (CCI-779) and 4-dimethylamino-but-2-enoic acid(4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinol in-6-yl)amide (EKB-569); synergistic; antitumor agents | WYETH | 2003-09-09 | — | — | US | disclosed |
| WO-2003020266-A1 | ANTINEOPLASTIC COMBINATIONS | WYETH (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030050222-A1 | Antineoplastic combinations | WYETH | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550107-B2 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | CYP4B1, CYP1B1, CYP2S1 | GABRP 533/4885GABRD 261/4885GABRA1 605/4885 |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | CYP4B1, CYP1B1, CYP2S1 | GABRP 533/4885GABRD 261/4885GABRA1 605/4885 |
| US-20030050222-A1 | Antineoplastic combinations | MCL1, BCL9, ERAL1 | GABRP 3383/4885GABRD 3527/4885GABRA1 2796/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | GABRP 4568/4885GABRD 4569/4885GABRA1 3632/4885 |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CDK9, CDK4, CDKL4 | GABRP 4239/4885GABRD 4137/4885GABRA1 4403/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | GABRP 2243/4885GABRD 2984/4885GABRA1 2530/4885 |
| US-12534742-B2 | Compound for regulating gene editing efficiency and application thereof | ERG, APOBEC3A, APOBEC3C | GABRP 1364/4885GABRD 597/4885GABRA1 247/4885 |
| US-20040162442-A1 | Synthesis of 4-(amino)-2-butenoyl chlorides and their use in the preparation of 3-cyano quinolines | HBS1L, ATXN2L, ASNS | GABRP 3647/4885GABRD 4115/4885GABRA1 1898/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | GABRP 1122/4885GABRD 2306/4885GABRA1 1080/4885 |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ERBB2, BRCA1, ERBB3 | GABRP 2023/4885GABRD 2108/4885GABRA1 2119/4885 |
| US-12630552-B2 | Inhibitors of KRAS G12C | KRAS, NRAS, HRAS | GABRP 1587/4885GABRD 862/4885GABRA1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.